CytomX Q2 2026 revenue $1.4M, cash $330.3M; Varseta-M registrational study planned for 1H 2027

CytomX Therapeutics, Inc.

Revenue $1.4M vs $18.7M YoY, driven by completion of BMS collaboration and lower Astellas activity.
Cash, equivalents and investments $330.3M; plus $37M July Regeneron payment; runway to 2H 2028.
Varseta-M Phase 1 data update expected end-2026; registrational study in CRC planned for 1H 2027.
Regeneron collaboration expanded; $37M target selection payment received; potential milestones up to ~$4B.
Board and leadership strengthened: Dr. Charles Fuchs, Mamata Gokhale, Alejandra Carvajal appointed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.